Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
29 jul 2009 - 07:44
Statutaire naam
Crucell N.V.
Titel
MVI and Crucell Announce Collaboration to test new Adenovirus-based Malaria Vaccine Approach
Bericht
Partners seek to protect against deadliest malaria parasite using virus-based transport method to deliver malaria antigen
Leiden, The Netherlands (July 29, 2009) – The U.S.-based PATH Malaria Vaccine Initiative (MVI), the United States Agency for International Development (USAID) Malaria Vaccine Development Program (MVDP) and Dutch biopharmaceutical company Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today announced a collaboration to accelerate development of a promising type of malaria vaccine. Through funding from the USAID MVDP, the partners will conduct studies to determine the effectiveness of Crucell’s novel prime-boost vaccine approach against the malaria parasite, Plasmodium falciparum. This approach uses Crucell’s proprietary recombinant adenoviruses (a type of virus associated with the common cold and other mild respiratory infections) to deliver a malaria antigen to the immune system.
Datum laatste update: 02 september 2024